Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

5.65
Delayed Data
As of Mar 24
 +0.13 / +2.36%
Today’s Change
4.03
Today|||52-Week Range
7.80
-3.58%
Year-to-Date

Today’s Trading

Previous close5.52
Today’s open5.54
Day’s range5.46 - 5.71
Volume1,025,794
Average volume (3 months)1,515,381
Market cap$608.3M
Dividend yield--
Data as of 3:59pm ET, 03/24/2017

Growth & Valuation

Earnings growth (last year)-27.73%
Earnings growth (this year)+55.13%
Earnings growth (next 5 years)+30.00%
Revenue growth (last year)+133.79%
P/E ratioNM
Price/Sales19.39
Price/Book--

Competitors

 Today’s
change
Today’s
% change
CRHMCRH Medical Corp-0.10-1.18%
ACIUAC Immune Ltd-0.02-0.18%
MGNXMacroGenics Inc+0.05+0.28%
ARDXArdelyx Inc-0.10-0.75%
Data as of 4:02pm ET, 03/24/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)-$0.20
Annual revenue (last year)$32.0M
Annual profit (last year)-$161.1M
Net profit margin-503.69%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Gregory P. Madison
Chief Operating Officer &
Senior Vice President
Christine A. Carberry
Corporate headquarters
Boston, Massachusetts

Forecasts


Search for Jobs